Last reviewed · How we verify
FULVESTRANT
FULVESTRANT is a Estrogen Receptor Antagonist [EPC] drug. It is currently FDA-approved (first approved 2002).
Fulvestrant is used in combination with endocrine therapies such as exemestane and letrozole to treat breast cancer, including HR+/HER2- breast cancer and metastatic disease. It is also being studied for the treatment of endometroid endometrial cancer.
At a glance
| Generic name | FULVESTRANT |
|---|---|
| Drug class | Estrogen Receptor Antagonist [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
Common side effects
- Injection site pain
- Nausea
- Bone pain
- Back pain
- Fatigue
- Pain in extremity
- Hot flash
- Vomiting
- Anorexia
- Asthenia
- Musculoskeletal pain
- Cough
Key clinical trials
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (PHASE3)
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (PHASE2)
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (PHASE2)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FULVESTRANT CI brief — competitive landscape report
- FULVESTRANT updates RSS · CI watch RSS
Frequently asked questions about FULVESTRANT
What is FULVESTRANT?
What drug class is FULVESTRANT in?
When was FULVESTRANT approved?
What development phase is FULVESTRANT in?
What are the side effects of FULVESTRANT?
Related
- Drug class: All Estrogen Receptor Antagonist [EPC] drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing